A novel berberine‐metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats

• DOI: 10.1111/1440-1681.13085
• Publication Date: 2019-03-19T03:28:52Z
• Authors: Dan Jia; Zi Wen Li; Xinxin Zhou; Ying Gao; Yifan Feng; Min Ma; Zhengzhi Wu; Weimin Li
• Keywords: Lipogenesis; Gluconeogenesis

Summary In this study, we investigated the biological activities of a novel berberine‐metformin hybrid compound ( BMH 473) as an anti‐diabetic agent. 473 exhibited significant anti‐hyperglycaemic and anti‐hyperlipidaemic effects on T2 DM rats. white adipose tissue, reduced perirenal epididymal tissue mass modulated lesions in by inhibiting protein expressions PPAR ‐Ɣ, C/ EBP ‐α SREBP ‐1c well mRNA lipogenic genes. Moreover, downregulated levels pro‐inflammatory cytokines through suppression p‐ NF ‐κB. liver, liver ectopic fat accumulation, regulating expression addition, inhibited hepatic gluconeogenesis promoting phosphorylation AMPK α ACC , down‐regulating FBP ase G6Pase PEPCK . Furthermore, inhibitory lipogenesis lipid accumulation 3T3‐L1 adipocytes modulating ‐1 c conclusion, our results suggest that newly synthesized is beneficial for maintaining glucose homeostasis type 2 diabetic rats, exhibits better compared to metformin berberine.